{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mukhopadhyay B"],"funding":["Intramural NIH HHS","U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism"],"pagination":["2869"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11063145"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(1)"],"pubmed_abstract":["Only ~20% of heavy drinkers develop alcohol cirrhosis (AC). While differences in metabolism, inflammation, signaling, microbiome signatures and genetic variations have been tied to the pathogenesis of AC, the key underlying mechanisms for this interindividual variability, remain to be fully elucidated. Induced pluripotent stem cell-derived hepatocytes (iHLCs) from patients with AC and healthy controls differ transcriptomically, bioenergetically and histologically. They include a greater number of lipid droplets (LDs) and LD-associated mitochondria compared to control cells. These pre-pathologic indicators are effectively reversed by Aramchol, an inhibitor of stearoyl-CoA desaturase. Bioenergetically, AC iHLCs have lower spare capacity, slower ATP production and their mitochondrial fuel fle"],"journal":["Nature communications"],"pubmed_title":["A patient-based iPSC-derived hepatocyte model of alcohol-associated cirrhosis reveals bioenergetic insights into disease pathogenesis."],"pmcid":["PMC11063145"],"funding_grant_id":["ZIA AA000301","ZIA AA000421"],"pubmed_authors":["Marietta C","Oiseni A","Shen PH","Mirshahi F","Yuan Q","Mukhopadhyay B","Hodgkinson C","Winkler E","Goldman D","Kunos G","Sanyal AJ","Mazzu M","Miranda D"],"additional_accession":[]},"is_claimable":false,"name":"A patient-based iPSC-derived hepatocyte model of alcohol-associated cirrhosis reveals bioenergetic insights into disease pathogenesis.","description":"Only ~20% of heavy drinkers develop alcohol cirrhosis (AC). While differences in metabolism, inflammation, signaling, microbiome signatures and genetic variations have been tied to the pathogenesis of AC, the key underlying mechanisms for this interindividual variability, remain to be fully elucidated. Induced pluripotent stem cell-derived hepatocytes (iHLCs) from patients with AC and healthy controls differ transcriptomically, bioenergetically and histologically. They include a greater number of lipid droplets (LDs) and LD-associated mitochondria compared to control cells. These pre-pathologic indicators are effectively reversed by Aramchol, an inhibitor of stearoyl-CoA desaturase. Bioenergetically, AC iHLCs have lower spare capacity, slower ATP production and their mitochondrial fuel fle","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-03-12T23:07:09.293Z","creation":"2025-08-12T03:05:03.292Z"},"accession":"S-EPMC11063145","cross_references":{"pubmed":["38693144"],"doi":["10.1038/s41467-024-47085-y"]}}